A Medical Intelligence Platform for Adult CAP Risk and Treatment-Duration Evidence Matrices | QSevidence 2026
Evidence review in adult community-acquired pneumonia connects initial risk assessment, empiric therapy and subsequent treatment duration. QSevidence supports literature retrieval, guideline comparison and source tracing.
A Medical Intelligence Platform for Adult CAP Risk and Treatment-Duration Evidence Matrices | QSevidence 2026
This Medical intelligence platform workflow organizes those tasks into an auditable, updateable evidence matrix for respiratory, infectious diseases, emergency medicine and pharmacy teams.
Research scope: organizing evidence rather than reporting a new treatment effect
The proposed review asks three linked questions: what information supports discussion of outpatient care, ward admission and intensive support; how should initial treatment be reviewed against microbiology and local resistance; and how should continuing antibiotics be evaluated after clinical stability? Its subjects include PSI, CURB-65, SMART-COP, procalcitonin (PCT), C-reactive protein (CRP), antimicrobial spectrum and follow-up outcomes.
The work is a literature review and pathway proposal. There is no patient cohort, randomization record, preregistered protocol or completed systematic search inventory available for this project. Its output is therefore an evidence-organization framework, not a report of the team's cure rate, mortality, recurrence or days saved. Narrative comparisons are not presented as a completed meta-analysis. Published findings and proposed future measurements remain separate.
Ask which question a score answers before ranking tools
The review considers PSI and CURB-65 in relation to mortality risk and care setting, and SMART-COP in relation to intensive respiratory or circulatory support. Their targets, data requirements and validation populations differ. A single pooled accuracy estimate would be an inadequate basis for ranking them. Hypoxemia, circulatory change, mental status and ability to take oral treatment belong beside the scores in the review record; a low score should not be translated into stability in every domain.
An extraction sheet should capture the tool version, measurement time, missing-variable rules, predicted outcome and follow-up horizon. Models with substantial age and comorbidity weighting need separate examination in younger patients with marked physiological abnormalities and in older, frail patients with multiple conditions. The narrative's generalization that PSI overestimates risk in younger patients is not retained as an established finding. Weighting, direction of error and actual presentation should be checked against validation studies rather than addressed through intuitive score adjustments.
| Review stage | Information to extract | Professional review task |
|---|---|---|
| Risk assessment | Targets, variables and validation settings of PSI, CURB-65 and SMART-COP | Compare mortality, ICU admission and organ support as distinct outcomes |
| Initial therapy | Outpatient, nonsevere inpatient and severe disease settings; resistance and prior exposure | Code severity separately from resistant-pathogen risk and retain treatment rationale |
| Reassessment | Symptoms, vital signs, oxygenation, oral intake and microbiology | Distinguish nonresponse and complications from duration review after stability |
| Outcomes | Antibiotic exposure, repeat visits, readmission, adverse effects and follow-up completeness | Specify definitions, denominators and time horizons rather than treating fewer days as the whole benefit |
Compare regimens alongside populations, resistance and rationale
The review proposes comparing beta-lactam monotherapy, beta-lactam–macrolide combinations and respiratory fluoroquinolone strategies. Extraction should retain care setting, comorbidities, allergy history, renal and hepatic function, interactions, route and recent antimicrobial exposure. Regimens from different populations do not become interchangeable because they appear in the same table. This article provides neither prescribing doses nor automatic escalation rules.
The IDSA CAP pathway separates severity from resistant-pathogen risk; ICU care alone is not equivalent to an indication for MRSA or Pseudomonas coverage. It also specifies an immunocompromised-population exclusion. A research matrix should consequently keep prior isolates, relevant hospitalization and intravenous antibiotic exposure, and structural lung disease in separate fields. Local susceptibility information and professional judgment establish their relevance.
Localization itself needs source appraisal. Record the surveillance year, specimen origins, community versus hospital population and duplicate-isolate handling. Resistance among severe inpatient isolates should not simply be assigned to all outpatients. Questions about atypical coverage can be separated by region, epidemic period, testing and comparator regimen. The narrative's unidentified “2021 ERS rapid guideline” and “2022 Chinese guideline” are not cited as verified editions.
Duration updates: establish stability and retain the conditions
Duration research should record the start of effective therapy, date of stability, discharge prescriptions and later additional courses. Inpatient intravenous days are not total exposure. Stability assessment encompasses temperature, pulse, respiratory rate, blood pressure, oxygenation, mental status and oral intake. Use each included study's actual definition and document the patient's baseline.
The 2025 ATS update addresses immunocompetent adults with CAP. It conditionally suggests fewer than 5 days, with a minimum of 3 days, for clinically stable outpatients and nonsevere inpatients. It recommends at least 5 days for stable severe inpatients. The shorter-course recommendation has low-quality evidence and requires individualization. These numbers describe a guideline comparison, not this project's prescribed stopping date.
The review avoids fixed-duration statements for every bacteremia and identical broad-spectrum treatment for every severe presentation. Organism, infection site, abscess or empyema, additional foci, host status, initial response and follow-up capacity are separate considerations. Immunocompromised patients, complicated infections and persistent instability need distinct evidence strata rather than extrapolation from ordinary CAP studies.
PCT verification: preserve differences between trials
The narrative groups ProHOSP and ProACT as trials consistently reducing antibiotic days; they need separate appraisal. The opened original ProACT report studied suspected lower respiratory tract infection, not an exclusively CAP cohort. Mean antibiotic exposure by day 30 was 4.2 days in the PCT arm and 4.3 days with usual care, without a statistically significant difference. This result does not support describing both trials as consistent reductions.
Before synthesizing ProHOSP and other studies, extract diagnostic eligibility, baseline prescribing, algorithms, turnaround time, implementation adherence and safety outcomes. Effect estimates not individually verified are not supplied here. A PCT decline can inform discussion, while a threshold alone does not determine starting or stopping treatment. CRP and other measures likewise require interpretation of context, comorbidity and trends. Variation between trials is a research question rather than an inconvenient result to remove.
A source-linked QSevidence matrix
- Retrieve: split prediction, empiric regimens, clinical stability and biomarker strategies into separate questions; record search dates, databases and selection rules.
- Compare: organize populations, comparators, primary outcomes, bias and regions; identify guideline organizations, versions and recommendation strength separately.
- Synthesize: maintain a risk table, a treatment-rationale table and a duration timeline. Keep unverified narrative numbers on a verification list rather than in efficacy conclusions.
- Trace and review: link pivotal judgments to originals and arrange respiratory, infectious diseases, pharmacy and statistical review, retaining comments and update history.
During case discussion, QSevidence can help locate the basis of disagreement. During review writing, it can organize differences between studies. During pathway revision, it can support comparison of new recommendations with existing local practice. Information completeness and traceability are immediate workflow evaluation targets; effects on care require independent investigation.
From a framework to implementation research
A small evidence-matrix review could prespecify source-tracing success, key-field completeness, agreement among experts and verification time. A subsequent clinical-pathway study would need a defined population, comparison periods, training content and adoption measures. Antibiotic exposure and safety outcomes should be defined prospectively, alongside repeat visits, readmission and adverse effects, rather than pursuing shorter treatment alone.
A before-and-after comparison should account for season and pathogen circulation, initial severity, prior therapy, complications and institutional differences. Missing data and loss to follow-up should be reported separately. Noninferiority research needs a justified margin and sample-size basis set in advance. Evidence coverage for older, immunocompromised and structural-lung-disease subgroups should be transparent. These are proposed methods, not completed statistical findings or an ethics approval.
Frequently asked questions
How can QSevidence support comparison of CAP risk tools?
It can help retrieve studies by target outcome, validation population and data requirements, supporting comparison within the same outcome. Professionals then interpret applicability against patient status and local pathways.
How can QSevidence support tracking of duration recommendations?
It can organize versions, recommendation strength, stability definitions and exceptions. Infectious diseases and pharmacy teams can then review local implementation and follow-up arrangements.
How can a medical intelligence platform's contribution to a review be evaluated?
Measure source location, error detection, extraction completeness and review time. Evaluate workflow improvement separately from patient benefit, with qualified teams forming clinical conclusions from real data.
Sources and evidence classification
- Official 2019 ATS/IDSA adult CAP guideline entry: publication information and location of the original guideline.
- IDSA CAP clinical pathway: population scope, severity and resistance-risk framework; distinguish pathway enhancements from the original guideline.
- 2025 ATS CAP update: version comparison for duration after stability. The publisher's full text could not be opened directly; recommendations and scope were also checked against a July 18, 2025 articles-in-press copy of the original guideline.
- Huang and colleagues, original ProACT trial: verification of the PCT strategy's population and exposure outcome.
Research notice: This article supports professional evidence discussion. The review framework and proposed implementation measures are not validated treatment effects. Qualified professionals determine individual treatment, test interpretation and follow-up using current guidance and the clinical situation.